Myhep All Tablet
Prescription Required
Marketed By
mylan pharmaceuticals
Pack of
28 tablet
Salt Composition
Sofosbuvir and Velpatasvir
Storage
Keep in cold place
₹7800₹17500
55.43% Off
Inclusive of all taxes
1
Myhep All Tablet
Delivering To: —
All Substitutes
Overview
Two antiviral medications are combined in Myhep All Tablet. Chronic hepatitis C virus (HCV) infection is treated with this prescription medication. The active ingredients of Myhep All tablets are Velpatasvir and Sofosbuvir. It helps by reducing the virus's ability to multiply within the body. Over time, a 400 mg Myhep tablet gradually improves liver function. The duration of time may vary depending on a number of factors, including liver cirrhosis, prior treatment history, and HCV genotype. Reducing the virus may significantly decrease the incidence of liver cirrhosis, liver failure, and hepatocellular carcinoma, a kind of liver cancer.
Indication
Hepatitis C
Uses
Chronic hepatitis C (HCV) infection.
Side Effects
MyhepAll 400 mg tablet may cause certain side effects. If side effects occur after administration or last longer than usual, contact your healthcare professional. Headache
Fatigue
Nausea
Insomnia
Diarrhea
Itching
Decreased appetite
Muscle or joint pain
Hepatitis B reactivation
Severe allergic reactions
Dosage and Administration
As directed by your physician, take this medication for the prescribed duration of time. Eat it all at once. Avoid chewing, crushing, or breaking it. It is preferable to take Myhep All Tablet at a set time, however it can be taken with or without food. Don't forget to take your medication. Tell your doctor if you fail to take your medications on time.
Mechanism of action
Sofosbuvir and Velpatasvir are two antiviral medications that are combined in Myhep All Tablet. They function by gradually removing the hepatitis C virus from the blood and reducing its levels in the body. By focusing on a particular protein required for viral reproduction, the direct-acting antiviral medication (DAA) sofosbuvir prevents the HCV virus from replicating. Another DAA that functions by preventing the activity of a different protein implicated in HCV replication is velpatasvir.
Safety Advice
Alcohol
unsafe
It is advisable not to consume alcohol while taking this medicine.
Pregnancy
consult your doctor
Do not take MyhepAll 400 mg tablet without consulting the doctor, in case of pregnancy.
Breast Feeding
consult your doctor
Without a doctor's consultation, do not take this medicine if you're breastfeeding.
Driving
danger
It is advisable not to drive or operate heavy machinery, you may feel dizzy as one of the side effects of the medicine.
Kidney
caution
Do not take Myhep 400 mg tablet without a doctor's consultation in case of kidney problems.
Liver
caution
Share your medical history with the doctor in case of liver disease before taking this medicine.
Missed Doses
It is suggested you that do not skip your medicines. If you forget to take your medication then contact your doctor immediately.
FAQs
Myhep All Tablet medicine is a combination of Sofosbuvir and Velpatasvir, which are also called antiviral medicines.
They work by fighting against of hepatitis C virus in the body and resolving the infection.
The common side effects of this medicine are headaches and fatigue.
During your treatment follow the suggestion which is given by your expert or doctor.
Take Myhep All Tablet as soon as you remember to do so. On the other hand, skip the missed dose and restart your usual routine if your next dose is almost due. Avoid taking two doses at once.
Yes, in order to track liver function, viral load, and treatment response, routine blood tests are usually performed during Myhep All pill treatment. These tests aid in determining the medication's efficacy and guarantee patient safety.
Trusted Medicines, Delivered Worldwide
At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.
Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.
Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.
We currently ship to:
Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!
Reference
Butt, N., Muhammad, I., Abou Bakr, A., Akhtar, Z., Ali, M., & Maheshwary, N. (2020). Efficacy and safety of Sofosbuvir-velpatasvir combination in Pakistani HCV patients without or with compensated cirrhosis. Cureus, 12(1), e6537. https://doi.org/10.7759/cureus.6537
Goel, A., Chen, Q., Chhatwal, J., & Aggarwal, R. (2018). Cost-effectiveness of generic pan‑genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment in India. Journal of Gastroenterology and Hepatology, 33(12), 2029–2036. https://doi.org/10.1111/jgh.14301
Tan, Y. M., et al. (2023). Real‑world impact of the subsidy decision of sofosbuvir‑velpatasvir for chronic hepatitis C: trends in utilization and SVR outcomes in Malaysia. JGH Open. https://doi.org/10.1002/jgh3.12850
Springer. Gaur, N., et al. (2020). Sofosbuvir‑velpatasvir fixed-dose combination for chronic hepatitis C infection in end-stage renal disease patients on maintenance hemodialysis: An Indian single-center experience. Journal of Clinical and Experimental Hepatology. Retrieved from PubMed. Shah, V., et al. (2023). Sofosbuvir/velpatasvir/voxilaprevir for retreatment of difficult-to-treat chronic HCV patients in India: Real-life observational cohort. Journal of Clinical and Experimental Hepatology. https://pubmed.ncbi.nlm.nih.gov/38261859/
Huang, C.-T., et al. (2021). Sofosbuvir/velpatasvir for chronic hepatitis C virus infection: real‑world effectiveness and safety from a nationwide registry in Taiwan. Infectious Diseases and Therapy, 10(3), 1185–1196. https://doi.org/10.1007/s40121-021-00576-7
Related Products
MARKETER DETAILS
mylan pharmaceuticals
DISCLAIMER
The contents of this website are for informative purposes only. They are not deliberated to be an alternative to any professional medical prescription and treatment. Seek the advice of a qualified health provider for questions regarding the medical condition. Do not ignore any professional medical advice because of something you have read on this website. This website offers links to other websites, thereby enabling you to go to the other website directly. Therefore, Magicine Pharma isn't responsible for the content of the links in the website or links in the linked websites. The links are provided to assist the visitors and are not approved by any professional health provider.